Key facts
- EcoR1 Capital, LLC filed SCHEDULE 13G/A for Apellis Pharmaceuticals, Inc. Common Stock (APLS).
- Disclosed ownership: 2.7%.
- Date of event: 30 Sep 2025.
EcoR1 Capital, LLC - 30 Sep 2025 SCHEDULE 13G/A Report for Apellis Pharmaceuticals, Inc. Common Stock (APLS)
- Filing Manager
- EcoR1 Capital, LLC
- Reporting Manager
- EcoR1 Capital, LLC
- Symbol
- APLS
- Shares outstanding
- 127,672,444 shares
- Disclosed Ownership
- 3,447,156 shares
- Ownership
- 2.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 15:45:16 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Key filing fact
EcoR1 Capital, LLC disclosed 2.7% ownership in Apellis Pharmaceuticals, Inc. Common Stock (APLS) on 30 Sep 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 15:45.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 2.7% | 3,447,156 | 0 | 3,447,156 | /s/ Oleg Nodelman | Manager | |
| Oleg Nodelman | 2.7% | 3,447,156 | 0 | 3,447,156 | /s/ Oleg Nodelman | Reporting person | |
| EcoR1 Capital Fund Qualified, L.P. | 2.5% | 3,219,256 | 0 | 3,219,256 | /s/ Oleg Nodelman | Manager of the General Partner, EcoR1 Capital, LLC |
CIK / CUSIP context first